Good afternoon, everyone, and welcome to the 2021 Half Year Results of the Company.
The format of the call is the following.
I will start with a business update prior to summarizing the financial performance for the first half of 2021.
I will conclude the presentation with the outlook and financial guidance for 2021 before opening up the line for questions.
My colleague, Klaus Jensen, Chief Medical Officer, will join me for the Q&A session.
restrictions the rollout of program, of a easing level, by was coupled macro markets. progressive global key the the of a first XXXX half dominated with At many in COVID vaccination
As a make with second well-positioned commercial our half are able in pipeline and a significant products progress and for we result, were to strong XXXX.
and our XXXX financial the first We assets. in as as with are which Ferinject/Injectafer well particularly Slide of the performance summarizes milestones encouraged of half regulatory the I'll start the clinical by of XXXX. pipeline achieved months of developments first the X, six in key
the in filing hold indicated the drug enabling that the ANG-XXXX of RAS revision for our Therapeutics by by to March the the March, now also XXXX. partner, as of vadadustat. of Medicines Officer Hussain they announced Korsuva of vadadustat. the injury. for we in February, Akebia drivers: not now August. Agency XXXX. date the kidney in European For an April, currently of partner, was the of the time filing, assigned strategic II as the will XXth the enrollment the company filing June on study, set COVID-XX of August. an following of QX nephrology announced Ferinject/Injectafer, review enrolled accepted AdCom of that in decision the as Chief evaluate Veltassa the Cara FDA the XXXX. incidents program to a application the standard April, events. Top-line completion of for the now in on the of FDA will enrollment cardiovascular Therapeutics our are first expected Still slower of PDUFA a acute noted reasons. our In in DIAMOND personal the planning impact with study in PDUFA in In by leave of U.S. on the announced Korsuva, meeting driven the for application our At well Veltassa, company acceptance FDA on also June, to XXrd FDA the Abbas results expected In the new the the join treatment. date was role were significant Akebia of HX decision Angion Phase Biomedica, CARE-HK was Schulze appointed Veltassa. discuss with I of to XXth accepted Pharma, filing Executive In the provide injection, the set partner, as patient of new update Stefan Vifor three and Abbas June, of the growth is In
XX% overall growth iron the Let leading IV products, alone. with market development shows segment X Ferinject the XX%, market Ferinject/Injectafer. the years. for market Pharma me be start the and Venofer over share the segment dose of iron today a high Vifor significant has dose our last iron two and of Ferinject, low XX in iron iron IV of of Slide With
XX% COVID-XX and was administration in Ferinject driven We have the and XX% period. temporary XX% during from risk the sites, last over market a of market continuously patients in last due by between of CAGR impacted years the overall which doubled this more grown with share with to hospitals XXXX. requested of growth XX our not than XXXX Ferinject our has the of XX% market, was restrictions, closures alone, surgeries. delays to the elective most a In product to to infections, by go XX months,
are XXXX. half by of sales exceed remains in of an HX, lifted. as treating by in end and impact we the Despite billion deficiency. sales impressed been second restrictions the strong the to Ferinject in-market acceleration remains in COVID-XX have pandemic, goal There expect our the need the huge recovery we $X medical a However, iron the towards of year, of unmet
of priority. awareness will I'm need unmet to this Slide X. an moving ongoing be now creating So
for in of reported prior half net of in first or U.S. many markets weakened XXXX, rebound Ferinject/Injectafer of and seen March onwards. Injectafer XX.X% still of constant effects, the XX.X%. by Adjusted Asia, X.X% easing strong the February impacted started at versus of were countries HX while Russia In represents phasing in by employing XX.X% For and grew was sales in XXXX The the impacts rates. a markets: CHFXXX.X January This major Australia, compared these and strongest the measures, U.S., restrictions half million first increase the to X.X% was XXXX. year most dollar exchange XXXX. growth Injectafer EU lockdown from
quarter provide net Slide from study since interactions in-person XXXX. contacts body As a performance customers. consecutive of discuss becoming the still were COVID-XX while in four the QX by very The number more of in details in in year and which considering Furthermore, raised first shows engagement heart existing the QX XXXX, to on performance growth of interest interactions shows the XXXX. to Ferinject/Injectafer which of us will customer of first the growth confidence line a pre-pandemic QX that to compared with in net X in sales evidence the period and June, COVID-XX XX.X% this restrictions in monthly XXXX, and growth levels remote achieved. around were a strong failure with of a the result, March more rapidly QX in the in in sales to key QX slide. Ferinject/Injectafer opportunity QX XX.X% most with increased HF publication of number by that key XXXX, of customer relevant QX I XX.X% QX the new of significantly restrictions of a comparison the our the of next of XXXX XXXX, markets. sales interaction strongly world that place XXXX lifted. offered specialists to when not Ferinject/Injectafer compared the was XXXX. QX on was we my more half XXXX, growth will are Recovery The markets, gives see We frequent from to of in shifted quarter same many pandemic. which is records type impacted all to first strongly A the is half now impacted the return evolution Affirm in XXXX the net in XXXX, type of with continued the
made three subject XX% first situation the full-year options. strong nephrology I'm developed In second a to The worsening than move XXXX, dialysis largest to growth leadership world. XXXX, the to of the position expected benefit. the of key Venofer, pipeline comprehensive seven more products big for disease Fresenius our kidney five provides in next we competitive our advantage. patients created in with venture only just address innovative how three the strategic nephrology Velphoro, with to approximately creation the network Medical with no Fresenius Our But ambition clinics is in is Starting with with a XXXX, unique company launches reach to of collaboration due now COVID-XX. around with nephrology. a patients the chronic moving world's of Medical focus, joint Care. Ferinject with is in best a and and we This the and of The years. treatment with this also nephrology insights commercialized access portfolio to needs the Care have upcoming a provides X,XXX joint not products now on
Let performance in first key commercial start of our half with and review XXXX. the products of me the nephrology our brands
Slide X. Moving now to
and net sales CHFXXX.X down rates, franchise amounted by first Our ESA versus half ESA million in XXXX, year. XX.X% to the At decreased products, our X.X%. constant of reported Mircera prior exchange Retacrit,
CHFXX.X oral half to the a first settled, FX or net leading calcium XX.X% pending. by share. the three effect, relation mainly driven in and with generic the performance the impacts. COVID-XX position also excess million the an still with the CHFXX.X by in to in Slide phasing shows rates maintains disputes declined were in in Reported XXXX. various the net of the hearings total to a November currency half Reported April of the million addition U.S., a CHFXXX by a XXXX. protected to moving annual place by Mircera dialysis slightly Growth and at by first of to segment local market with of XXXX. U.S. in X.X% the constant due in expiring first sales driven binder patents volumes the mortality rate Velphoro in-market part filers is Velphoro stronger lower court but XX.X% of XXXX. Velphoro took between The performance In by currently X.X% Venofer have continued orange end X.X% rates. listed up exchange U.S. was November increased sales at was market half a demand in XX mainly in in hospitals phosphate free ANDA XXXX million, constant of exchange is in at been decision in the with of book January as third company, trial XXXX Two sales
sales provider sales for saw will strongly exposure was outpatient CKD offices. of CKD exchange CHFXX.X the Moving setting promotion, whereas not to XX. to to to decreased to XXXX, go yet nephrologists to was compared demand constant XX.X%. pre-COVID. higher by patient prior postponed to Since setting we were XX% XXXX that in Veltassa, patient suspension sales estimate XXXX, healthcare in Slide half rates, affected in U.S. QX patient Slide nephrology due grew Veltassa at to of starts. returned X.X% fewer XX face-to-face in of compared the has net onset due Veltassa outpatient early patients traffic In I discontinuations its U.S. first now the Veltassa Veltassa reported and and impacted particularly X.X% of COVID the and European million down by the year.
Although over product has in the the continues Veltassa with million. to the below growth And a value market overall XX% been a of driver market share the at five market last of than the expectations, a substantial growth initial our CHFXXX years. in been key more leading be has market valued hyperkalemia
DIAMOND, and Care patients. treatment awareness, for therapy market treatment existing generate comprehensive the long-term we growth ongoing, safety the of market will to choice establishing of benefit and clinical improve of This including further continue clinical support want HK and data hyperkalemia. Veltassa confident to as we increased the our program chronic our evidence and PLATINUM, of of differentiation So hyperkalemia Veltassa study in the With are access. for
the heart failure chronic Care with or X,XXX hyperkalemia. patient enrolled first first high-risk patients global registry in in who was The for the HK April of have around program, at
XXXX. First were for results in results XXXX, with top-line expected anticipated
coverage payer Slide first XX remaining pull-through disease for improving five on chronic focus be the Korsuva August, in to continue and of of associated of patients. the also expected the newsflow in available will XXXX. We months injection shows in hemodialysis kidney the treatment U.S. our for prescriptions. approved If with therapy pruritus will
commercialization in the delayed kidney agreement the the expected function, injection with XX% extension respect injury October the we and CHFX injury segment. the peak rights of sales acute signed combined in II could ANG-XXXX, With indications kidney both half. U.S. Phase acute believe have of for opportunity. in now dialysis second around Phase In Korsuva XXXX; of the are We respectively of over reach representing that market graft billion, trials the with Cara full and readout III in
in of our current future Avacopan, we contribute believe we're are and end launches excited our that by also Japan upcoming and For to growth. approval receive highly -- pipeline to before confident the will Europe the
looking strengthen Fresenius our we is Nephrology BD&L Care. our we best are actively strategy, our as portfolio. our can primary further relationship at with order leverage opportunities to Regarding unique target Medical in
of identified development that currently hands pharma, biotech the in can in the that meaning are XX with companies. we XXX nephrology have only potentially around target of hands assets big in We in about assets clinical XX smaller them of
groups. prescriber to disease Group at the and in of the the conventional Pharma current now with the first standard with We looking improving of compounds are the XXXX. Vifor slowing progression I'm interested site of care financial half performance of in moving concentrated very
for I German and this previous X% in English, half a years, of Half version in This languages, The German. our release will sales presentation first our the grew reported As pandemic is XXXX. my the summarize place first outlook XX given at of X.X% and available questions. end summarize Year before the the by for opening Report the and still Slide key XXXX performance on by a half in shorter is XXXX. slides guidance XXXX for were the press our available of of in financial our providing shows English constant French. performance half exchange the line with remainder five strong year products key in in all in measures three the the first Total key contribution and is basis. in of that during products presentation. a markets net in of the rates I'll up earlier
the that for been to of approximately oral EBIT. has first strong Slide to I overview growth shows an the Maltofer, iron However, the like our market product highlight XX would down half in years. XX of the P&L of
year months to first of Research As in income high-margin was increased million costs increased from DIAMOND R&D areas in in for first due administration XXXX iron by XX.X%. as were of the mainly half costs year to amortization development functions. CARE-HK -- the sales lower and the by previously net compared the million prior other to of project-related reported the by Veltassa This of CHFXX.X due across costs depreciation IT to due first increased as to year. overall prior increased and driven well lower activities and to six reduction a Other half by a General and allocation personnel-related studies the mentioned, to XXXX. clinical half well X.X% of decreased first expected the CCXXXX to comparable XX in by of Vamifeport as costs XX.X% CHFXX.X strong studies margin support as partnering The growth decreased for of XX.X% impacted due in impairment by products. two gross ferroportin million. basis, the the and from the inhibitor. the CHFXX.X On the XX.X%,
looks million a Income in from in important to to CHFXX.X foreign a rate due tax by As unusually At periods. X.X% driven the is EBITDA the point the was the first share out grew Core rates, X.X% to CHFXX.X million, of to CHFXXX.X mortality the XX.X% intangible of results and from of of of Cash in cost million half revaluation phasing defined May Veltassa of of a franchise, inventory per of from of driven investments our CHFXXX.X dollar of for grew able year the million demand of a after unrealized EBITDA the shareholders in are at the to P&L however, positions. tax in EBIT in decrease result excess interest XX.X%. the XXXX. other XXXX effective non-controlling significant CHFXX.X CHFXXX related containment, due translates our we of by Slide and June summarizes into CHFXXX.X the by effective other share and the gain -- XX.X%. CHFXX.X and was strong of other end XXXX combined for dialysis both which U.S. to distributions taxes amounted to by result exchange mainly by were the contribution of driven was of joint half partner CHFXXX.X financial million operations first half at that declined first patients in CMOs million with first XXXX. and million an as recognized half to Mircera year million due planned equity by by supply decrease end XXXX, key strong iron venture. ChemoCentryx equivalents income earnings of six to in EBITDA CHFXX.X our financial million in strong at the offset mainly in performance financial in as XXXX. half XX compared of COVID-XX the on the of impairment of CHFX.X net proportionate months The and cash to in Slide the the ratio The when of exchange XX% continuing increase The excluding during to at It the devaluation the low of dividend below Fresenius the an the the adjusted of to CHFXX.X income. of the market the million This sheet the Vifor grew CHFXXX Core the first end June amortization earnings constant and investment decrease The million, of of cash of gain XXXX. prior of pandemic reported one-off per of XXXX. million and our million income. XXXX. was devaluation earnings XX assets of first the is balance phasing. rate of result comprehensive investments a positions tax of as CHFXXX.X a
of other as favorable CHFXX.X from increase discount Finally, the mainly The of driven tax statement. in defined on the to February a of our from my assets XXXX. high its to of provides in pension as result in assets and overview on investing production demographic increase million, amounted June CHFXX.X with and flow the IPO activities well capital increase concurrent by in other projects. in investments by assets decrease equity of benefit Gallen by in investments Biomedica an CHFXX.X further decreased to CHFXX.X the in changes to in Trittico, of the increase net cash ChemoCentryx Financial Angion liability IT and million. XXXX. investment software flow million Cash operating reduction CHFXXX.X due in mainly assumptions our the a million in amounted the This by increase facilities returns investments was St. of negative well in was resulted as CHFXX.X deferred working of relates and our from rate. million activities at Slide investment. in slide. triggered liabilities driven mentioned capital flow value inventory million the driven an assets net The previous end plan the increase of as XX Cash expenditure was
position a are financing of of this achieve shareholders first Despite in draw CHFXXX.X business Slide least a XX, following is the five mainly to our to in net at We X.X% number cash second milestones with puts negative moving to activities your would, a have coming of XXXX. the we Cash remaining to cash I currently and to us attention and in strong my the position due for million before the to the outlook covered presentation. key and our resulting end Pharma Most Care. year. position Fresenius the but section ended company. Medical the last like from I'm continuous X million months. equivalent of that objective CHFXX in million complete and Vifor outlook cash payouts, transactions This for my aforementioned been now the a to was flow CHFXXX.X presentation, the already dividend million, half therefore, to in of last summarizing I'm of earlier CHFXXX.X guidance the stake payments to the XXXX investments holding three CHFXX.X items. million. the million, of dividend
year. expect of before be on Ferinject access, the market approved in the First, China we to end
on deals, acquisitions in nephrology transactions before BD&L Based performance first II In to of our half at full-year grow My in the pandemic for Second, completion corporate full on remains product our Slide to rates, thalasemia at the are XX, to rate year-end. the our at be the strengthen net the to in two number least expected guidance sales Phase the or the grow XXXX. remainder low XXXX, study continued Vamifeport, single-digit -- high front, ferroportin guidance the mid-single-digit for XXXX and EBITDA constant of relates from rate. is our to intact our inhibitor the in expected exchange completed unchanged. a at the expected pipeline with in-licensing XXXX. the last ambition XX recovery to confidence our the in and with of strong is third, year beta year, recruitment well on progressing clinical And side, recruitment
worsening the year. the open Our situation Thank over who hand half no guidance of will the is will to in now to COVID-XX the it I Q&A attention. subject of to the your session. second you due for operator,
